Volume 15, Number 7—July 2009

Research

Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure¹

Susan J. Howard, Dasa Cerar, Michael J. Anderson, Ahmed Albarrag, Matthew C. Fisher, Alessandro C. Pasqualotto, Michel Laverdiere, Maiken C. Arendrup, David S. Perlin, and David W. Denning 

Author affiliations: Regional Mycology Laboratory, Manchester, UK (S.J. Howard, D.W. Denning); University of Manchester, Manchester Academic Health Science Centre, Manchester (S.J. Howard, M.J. Anderson, A. Albarrag, D.W. Denning); University Medical Centre, Ljubljana, Slovenia (D. Cerar); Imperial College, London, UK (M.C. Fisher); Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (A.C. Pasqualotto); Hôpital Maisonneuve-Rosemont, Montreal, Québec, Canada (M. Laverdiere); Statens Serum Institut, Copenhagen, Denmark (M.C. Ardendrup); Public Health Research Institute, Newark, NJ, USA (D.S. Perlin)

Main Article

Figure 1

Figure 1. Azole resistance in clinical Aspergillus fumigatus isolates received in the Regional Mycology Laboratory Manchester, UK, 1997–2007. Overall azole resistance for each year is shown above each column as a percentage. Data do not include sequential isolates from the same patient.

Main Article

¹These data were presented in part at the 2nd Advances Against Aspergillosis meeting, February 22–26, 2006, Athens, Greece; and 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27–30, 2006, San Francisco, CA, USA.

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.